No. SB 1070
Filed under Insurance.
State Group Insurance Program Coverage for Obesity Treatment; Requiring the Department of Management Services to provide coverage for specified strategies for the evidence-based treatment and management of obesity and related conditions for state group health insurance plan policies issued on or after a specified date; prohibiting coverage criteria for weight management medications from being more restrictive than the United States Food and Drug Administration’s indications for such medications, etc.
Plain English Summary
AI-GENERATEDStarting with policies issued on or after January 1, 2027, the state group health insurance program must cover GLP-1 weight-loss medications and intensive behavioral or lifestyle treatment for obesity, when prescribed by a licensed provider.
Coverage criteria for these medications cannot be stricter than the FDA's own approved uses for them, though the department can still add other clinical and participation requirements to manage cost.
To qualify, an employee must be 18 or older, diagnosed with obesity and referred by an in-network provider, and must also take part in the behavioral and lifestyle intervention, not medication alone.
AIRequires the department to cover intensive health behavioral and lifestyle intervention and FDA-approved weight management medications for state group health plan policies issued on or after January 1, 2027, when prescribed by a licensed provider.
AIBars the department from applying coverage criteria for weight management medications that are stricter than what the FDA itself has approved the medication for, limiting how much the state can narrow access through utilization rules.
AIAn employee receiving coverage under this subsection must also participate in the intensive health behavioral and lifestyle intervention, so medication coverage is conditioned on also engaging in the behavioral program.
AITo qualify for coverage, an employee must be referred to and supervised by an in-network licensed provider and must have received a clinical obesity diagnosis from an in-network provider, not any outside specialist.
AIGives the department authority to impose additional clinical and participation requirements, beyond the ones listed, specifically to manage the cost of coverage, without specifying what those requirements might be.
AIDefines the covered medication narrowly as a GLP-1 agonist drug approved by the FDA for chronic weight management, not any FDA-approved weight-loss medication regardless of drug class.
AIRequires the department to report participation levels and cost savings to the enrollee and the state each year to the Governor and the leaders of both legislative chambers.